{"id":70765,"date":"2026-05-12T10:53:49","date_gmt":"2026-05-12T10:53:49","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70765"},"modified":"2026-05-21T07:14:09","modified_gmt":"2026-05-21T07:14:09","slug":"cagrisema","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/cagrisema\/","title":{"rendered":"CagriSema sm\u011bs (Cagrilintide 5 mg + Semaglutide 5 mg)"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Rychl\u00e1 odpov\u011b\u010f \u2014 Co je CagriSema?<\/h3>\n<p style=\"margin: 0;\"><strong>CagriSema<\/strong> je kombinovan\u00e1 formulace <a href=\"https:\/\/medsbase.com\/cs\/cagrilintide\/\">cagrilintide<\/a> (dlouhodob\u011b p\u016fsob\u00edc\u00ed analog amylinu) a <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">semaglutide<\/a> (dlouhodob\u011b p\u016fsob\u00edc\u00ed agonista GLP-1) v jedn\u00e9 lyofilizovan\u00e9 lahvi\u010dce. Jde o hlavn\u00ed program f\u00e1ze 3 pro obezitu od spole\u010dnosti Novo Nordisk, kter\u00fd v pr\u016fb\u011bhu 68 t\u00fddn\u016f ve studii REDEFINE-1 dos\u00e1hl sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti p\u0159ibli\u017en\u011b o 20\u201323 % \u2013 \u00fa\u010dinek srovnateln\u00fd s trojit\u00fdm agonistou <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">retatrutide<\/a> dosa\u017een\u00fd kombinac\u00ed dvou agonist\u016f p\u016fsob\u00edc\u00edch na jeden receptor nam\u00edsto jedn\u00e9 molekuly s v\u00edce agonistick\u00fdmi \u00fa\u010dinky. Ka\u017ed\u00e1 lahvi\u010dka obsahuje 5 mg cagrilintidu + 5 mg semaglutidu v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> Lyofilizovan\u00e1 sm\u011bs peptid\u016f pro v\u00fdzkumn\u00e9 \u00fa\u010dely \u00b7 HPLC \u010distota \u226599 % (ka\u017ed\u00e1 slo\u017eka, certifik\u00e1t anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 V\u00edce ne\u017e 1 400 ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifikace<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Slo\u017een\u00ed<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cagrilintide 5 mg + Semaglutide 5 mg na lahvi\u010dku (hmotnostn\u00ed pom\u011br 1:1, kombinovan\u00e1 formulace)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Celkov\u00fd peptid na lahvi\u010dku<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">10 mg celkov\u00e9 hmotnosti peptidu (5 mg + 5 mg)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>\u010c\u00edsla CAS slo\u017eek<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">1415456-99-3 (cagrilintide) \/ 910463-68-2 (semaglutide)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Profil receptor\u016f<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Rodina receptor\u016f amylinu \/ kalcitoninu (AMY1\/2\/3) <em>plus<\/em> Receptor GLP-1 \u2013 mechanisticky komplement\u00e1rn\u00ed, nep\u0159ekr\u00fdvaj\u00edc\u00ed se<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item11<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd kombinovan\u00fd pr\u00e1\u0161ek (b\u00edl\u00fd a\u017e sv\u011btle b\u00e9\u017eov\u00fd)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item13<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226599 % (ka\u017ed\u00e1 slo\u017eka ov\u011b\u0159en\u00e1 HPLC, certifik\u00e1t anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Polo\u010das rozpadu (podle slo\u017eky)<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Cagrilintid ~159 hodin; Semaglutid ~165 hodin \u2014 oba podporuj\u00ed t\u00fddenn\u00ed subkut\u00e1nn\u00ed d\u00e1vkov\u00e1n\u00ed<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Skladov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00e9: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00e9: 2\u20138 \u00b0C, pou\u017eijte do ~30 dn\u016f. Chra\u0148te p\u0159ed sv\u011btlem. Nefreeze\u2013thaw rekonstituovan\u00fd roztok.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Rozpustnost<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakteriostatick\u00e1 voda (doporu\u010deno). Oba peptidy se rekonstituuj\u00ed sou\u010dasn\u011b ze stejn\u00e9 lahvi\u010dky.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pouze pro v\u00fdzkum<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Co je CagriSema?<\/h2>\n<p><strong>CagriSema<\/strong> je v\u00fdvojov\u00fd n\u00e1zev spole\u010dnosti Novo Nordisk pro fixn\u00ed pom\u011br kombinace dvou dlouhodob\u011b p\u016fsob\u00edc\u00edch peptid\u016f v jedn\u00e9 subkut\u00e1nn\u00ed formulaci: <a href=\"https:\/\/medsbase.com\/cs\/cagrilintide\/\">cagrilintide<\/a> (dlouhodob\u011b p\u016fsob\u00edc\u00ed analog amylinu, v\u00fdvojov\u00fd k\u00f3d AM833) a <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">semaglutide<\/a> (dlouhodob\u011b p\u016fsob\u00edc\u00ed agonista receptoru GLP-1 prod\u00e1van\u00fd jako Ozempic a Wegovy jako samostatn\u00fd p\u0159\u00edpravek). Tato kombinace je hlavn\u00edm programem f\u00e1ze 3 pro obezitu v portfoliu spole\u010dnosti Novo Nordisk a v letech 2024\u20132025 p\u0159inesla v\u00fdsledky studie REDEFINE-1: p\u0159ibli\u017en\u011b 20\u201323% sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti za 68 t\u00fddn\u016f p\u0159i t\u00fddenn\u00ed d\u00e1vce 2,4 mg + 2,4 mg \u2014 \u00fa\u010dinnost, kter\u00e1 \u0159ad\u00ed CagriSemu do stejn\u00e9 kategorie jako trojit\u00fd agonista receptoru <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">retatrutide<\/a> p\u0159i\u010dem\u017e vyu\u017e\u00edv\u00e1 zcela odli\u0161n\u00fd farmakologick\u00fd p\u0159\u00edstup.<\/p>\n<p>Strategick\u00e9 zd\u016fvodn\u011bn\u00ed pro CagriSemu spo\u010d\u00edv\u00e1 v <strong>dopl\u0148kov\u00fdch, nep\u0159ekr\u00fdvaj\u00edc\u00edch se mechanismech<\/strong> jej\u00edch dvou slo\u017eek. Agonist\u00e9 receptoru GLP-1 (semaglutid) p\u016fsob\u00ed p\u0159ev\u00e1\u017en\u011b na neurony POMC v hypothalamick\u00e9m j\u00e1dru arcuate (centr\u00e1ln\u00ed regulace chuti k j\u00eddlu) a na beta-bu\u0148ky slinivky b\u0159i\u0161n\u00ed (gluk\u00f3za-dependentn\u00ed sekrece inzul\u00ednu). Agonist\u00e9 receptoru amylinu\/kalcitoninu (cagrilintid) p\u016fsob\u00ed p\u0159ev\u00e1\u017en\u011b na neurony area postrema v mozkov\u00e9m kmeni (pos\u00edlen\u00ed sytosti po j\u00eddle) a na alfa-bu\u0148ky slinivky b\u0159i\u0161n\u00ed (potla\u010den\u00ed glukagonu). Tyto mechanismy se mechanicky s\u010d\u00edtaj\u00ed, nikoli p\u0159ekr\u00fdvaj\u00ed, co\u017e je d\u016fvod, pro\u010d kombinace vykazuje v\u00fdrazn\u011b v\u011bt\u0161\u00ed \u00fa\u010dinky na t\u011blesnou hmotnost ne\u017e ka\u017ed\u00e1 slo\u017eka samostatn\u011b \u2014 co\u017e bylo prok\u00e1z\u00e1no ve f\u00e1zi 2 p\u0159\u00edm\u00e9ho srovn\u00e1n\u00ed, kde CagriSema p\u0159ekonala jak monoterapii cagrilintidem, tak monoterapii semaglutidem.<\/p>\n<p>Tato v\u00fdzkumn\u00e1 formulace CagriSemy obsahuje <strong>5 mg cagrilintidu + 5 mg semaglutidu na lahvi\u010dku<\/strong> v hmotnostn\u00edm pom\u011bru 1:1, kter\u00fd odpov\u00edd\u00e1 fixn\u00edmu d\u00e1vkov\u00e9mu pom\u011bru pou\u017e\u00edvan\u00e9mu v klinick\u00e9m programu f\u00e1ze 3. Ob\u011b slo\u017eky jsou p\u0159edem sm\u00edch\u00e1ny ve stejn\u00e9 lyofilizovan\u00e9 lahvi\u010dce; rekonstituce bakterio-statickou vodou vytvo\u0159\u00ed pracovn\u00ed roztok obsahuj\u00edc\u00ed oba peptidy sou\u010dasn\u011b. Tento p\u0159\u00edstup eliminuje nutnost kombinovat samostatn\u00e9 lahvi\u010dky p\u0159i p\u0159\u00edprav\u011b. CagriSema nen\u00ed <strong>FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> schv\u00e1lena FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed podle sou\u010dasn\u00e9 literatury; regula\u010dn\u00ed pod\u00e1n\u00ed a p\u0159ezkum prob\u00edhaj\u00ed. V\u00fdzkumn\u00e1 CagriSema prod\u00e1van\u00e1 zde je dod\u00e1v\u00e1na <strong>ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed ur\u010den pro pod\u00e1v\u00e1n\u00ed lidem nebo zv\u00ed\u0159at\u016fm. Pro podrobn\u011bj\u0161\u00ed informace o jednotliv\u00fdch slo\u017ek\u00e1ch viz na\u0161e individu\u00e1ln\u00ed <a href=\"https:\/\/medsbase.com\/cs\/cagrilintide\/\">Cagrilintide<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a> produktov\u00e9 str\u00e1nky.<\/p>\n<h2>Mechanismus \u00fa\u010dinku \u2014 Komplement\u00e1rn\u00ed farmakologie dvojit\u00e9ho receptoru<\/h2>\n<p>To, co \u010din\u00ed CagriSema mechanisticky v\u00fdjime\u010dnou mezi sou\u010dasn\u00fdmi metabolick\u00fdmi v\u00fdzkumn\u00fdmi slou\u010deninami, je skute\u010dnost, \u017ee dv\u011b slo\u017ekov\u00e9 peptidy aktivuj\u00ed <strong>zcela odli\u0161n\u00e9 rodiny receptor\u016f s nep\u0159ekr\u00fdvaj\u00edc\u00edmi se centr\u00e1ln\u00edmi a perifern\u00edmi mechanismy<\/strong> \u2014 dosahov\u00e1n\u00ed v\u00edceos\u00e9 farmakologie prost\u0159ednictv\u00edm kombinace sp\u00ed\u0161e ne\u017e prost\u0159ednictv\u00edm konstrukce jedn\u00e9 molekuly s v\u00edce agonisty, jako je tirzepatid nebo retatrutid:<\/p>\n<ul>\n<li><strong>V\u011btev receptoru GLP-1 (semaglutid) \u2014 centr\u00e1ln\u00ed regulace chuti k j\u00eddlu a kontrola glyk\u00e9mie<\/strong> \u2014 Semaglutid aktivuje receptor GLP-1 na POMC neuronech hypotalamick\u00e9ho j\u00e1dra arcuate (potla\u010dov\u00e1n\u00ed p\u0159\u00edjmu potravy prost\u0159ednictv\u00edm centr\u00e1ln\u00edho syst\u00e9mu chuti k j\u00eddlu), pankreatick\u00fdch beta-bu\u0148k\u00e1ch (gluk\u00f3za-dependentn\u00ed sekrece inzul\u00ednu), pankreatick\u00fdch alfa-bu\u0148k\u00e1ch (potla\u010den\u00ed glukagonu) a gastrick\u00fdch vag\u00e1ln\u00edch aferentech (opo\u017ed\u011bn\u00e9 vyprazd\u0148ov\u00e1n\u00ed \u017ealudku). Tato v\u011btev poskytuje kanonickou inkretinovou farmakologii, za kterou jsou semaglutid a dal\u0161\u00ed agonist\u00e9 GLP-1 zn\u00e1m\u00ed v publikovan\u00e9m v\u00fdzkumu a schv\u00e1len\u00e9m klinick\u00e9m pou\u017eit\u00ed.<\/li>\n<li><strong>V\u011btev amylinov\u00e9ho \/ kalcitoninov\u00e9ho receptoru (cagrilintid) \u2014 sytost v mozkov\u00e9m kmeni a zp\u011btn\u00e1 vazba na j\u00eddlo<\/strong> \u2014 Cagrilintid aktivuje heterodimery amylinov\u00e9ho receptoru (AMY1, AMY2, AMY3 \u2014 kalcitoninov\u00fd receptor + RAMP1\/2\/3) um\u00edst\u011bn\u00e9 hust\u011b v oblasti postrema mozkov\u00e9ho kmene, CNS oblasti, kter\u00e1 postr\u00e1d\u00e1 hematoencefalickou bari\u00e9ru. To vytv\u00e1\u0159\u00ed pos\u00edlen\u00ed sytosti na jin\u00e9m \u010dasov\u00e9m vzoru ne\u017e tonick\u00e9 centr\u00e1ln\u00ed potla\u010den\u00ed chuti k j\u00eddlu GLP-1. Amylinov\u00e1 v\u011btev tak\u00e9 oddaluje vyprazd\u0148ov\u00e1n\u00ed \u017ealudku \u010d\u00e1ste\u010dn\u011b odli\u0161nou vag\u00e1ln\u00ed cestou a potla\u010duje postprandi\u00e1ln\u00ed glukagon v pankreatick\u00fdch alfa-bu\u0148k\u00e1ch.<\/li>\n<li><strong>Aditivn\u00ed vs. synergick\u00fd \u00fa\u010dinek na fenotyp t\u011blesn\u00e9 hmotnosti<\/strong> \u2014 Data z f\u00e1ze 2 p\u0159\u00edmo porovn\u00e1vaj\u00edc\u00ed \u00fa\u010dinky p\u0159edstavuj\u00ed nej\u010dist\u0161\u00ed d\u016fkaz aditivn\u00ed (a mo\u017en\u00e1 synergick\u00e9) farmakologie: monoterapie cagrilintidem v d\u00e1vce 2,4 mg t\u00fddn\u011b vedla k redukci t\u011blesn\u00e9 hmotnosti ~10 %; monoterapie semaglutidem v d\u00e1vce 2,4 mg t\u00fddn\u011b vedla k redukci ~15 %; kombinace CagriSema v d\u00e1vce 2,4 + 2,4 mg vedla k redukci ~20\u201323 %. \u010cist\u00fd efekt se bl\u00ed\u017e\u00ed nebo p\u0159ekra\u010duje sou\u010det jednotliv\u00fdch \u00fa\u010dink\u016f, co\u017e odpov\u00edd\u00e1 mechanistick\u00e9 predikci, \u017ee sou\u010dasn\u00e1 aktivace dvou neprot\u00ednaj\u00edc\u00edch se cest sytosti vytv\u00e1\u0159\u00ed siln\u011bj\u0161\u00ed anorektick\u00fd sign\u00e1l ne\u017e ka\u017ed\u00e1 z nich samostatn\u011b.<\/li>\n<\/ul>\n<p>Oba peptidy jsou acylov\u00e1ny mastn\u00fdmi diacylov\u00fdmi \u0159et\u011bzci, kter\u00e9 se reverzibiln\u011b v\u00e1\u017eou na cirkuluj\u00edc\u00ed s\u00e9rov\u00fd albumin (cagrilintid vyu\u017e\u00edv\u00e1 C20 \u0159et\u011bzec p\u0159es \u03b3-Glu-OEG-OEG; semaglutid vyu\u017e\u00edv\u00e1 C18 p\u0159es \u03b3-Glu-AEEA-AEEA). Polo\u010dasy jsou dob\u0159e slad\u011bny na ~159 hodin (cagrilintid) a ~165 hodin (semaglutid) \u2014 oba podporuj\u00ed subkut\u00e1nn\u00ed pod\u00e1v\u00e1n\u00ed jednou t\u00fddn\u011b bez rozd\u00edln\u00e9 farmakokinetiky. Toto farmakokinetick\u00e9 slad\u011bn\u00ed je jednou z konstruk\u010dn\u00edch vlastnost\u00ed, kter\u00e9 umo\u017e\u0148uj\u00ed praktickou koformulaci v jedn\u00e9 lahvi\u010dce: ob\u011b slo\u017eky mohou b\u00fdt rekonstituov\u00e1ny, skladov\u00e1ny a pod\u00e1v\u00e1ny spole\u010dn\u011b, ani\u017e by byla naru\u0161ena expozice kter\u00e9koliv z nich.<\/p>\n<h2>Publikovan\u00e9 v\u00fdzkumn\u00e9 aplikace<\/h2>\n<p>V\u00fdzkumn\u00e9 peptidy CagriSema koformulace se pou\u017e\u00edvaj\u00ed v laboratorn\u00edch kontextech, kter\u00e9 zkoumaj\u00ed:<\/p>\n<ul>\n<li><strong>Kombinovanou farmakologii obezity<\/strong> \u2014 hlavn\u00ed program: preklinick\u00e9 modely ob\u00e9zn\u00edch hlodavc\u016f (DIO), t\u011blesn\u00e9 slo\u017een\u00ed (DEXA\/MRI), testy p\u0159\u00edjmu potravy, charakterizace energetick\u00e9ho v\u00fddeje; p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed s rameny monoterapie (samotn\u00fd cagrilintid, samotn\u00fd semaglutid) k rozli\u0161en\u00ed aditivn\u00edho vs. synergick\u00e9ho \u00fa\u010dinku (Enebo et al., Lancet 2021; v\u00fdsledky f\u00e1ze 3 REDEFINE-1 \/ REDEFINE-2)<\/li>\n<li><strong>Preklinick\u00fd v\u00fdzkum diabetu 2. typu<\/strong> \u2014 glykemickou kontrolu, n\u00e1hradn\u00ed markery HbA1c, postprandi\u00e1ln\u00ed dynamiku gluk\u00f3zy u model\u016f db\/db a hlodavc\u016f na vysokotu\u010dn\u00e9 diet\u011b<\/li>\n<li><strong>Srovn\u00e1vac\u00ed v\u00fdzkum multiagonist\u016f<\/strong> \u2014 p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed s jednomolekulov\u00fdmi multiagonisty v\u010detn\u011b <a href=\"https:\/\/medsbase.com\/cs\/tirzepatide\/\">Tirzepatide<\/a> (du\u00e1ln\u00edch GLP-1\/GIP), <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> (trojit\u00fdch GLP-1\/GIP\/glukagon), <a href=\"https:\/\/medsbase.com\/cs\/mazdutide\/\">Mazdutide<\/a> (du\u00e1ln\u00edch GLP-1\/glukagon), a <a href=\"https:\/\/medsbase.com\/cs\/survodutide\/\">Survodutide<\/a> (du\u00e1ln\u00edch GLP-1\/glukagon); kl\u00ed\u010dovou ot\u00e1zkou je, zda farmakologie kombinace dvou molekul m\u00e1 n\u011bjakou v\u00fdhodu oproti jednomolekulov\u00fdm multiagonist\u016fm<\/li>\n<li><strong>V\u00fdzkum interakce osy amylin\/GLP-1<\/strong> \u2014 charakterizace neprot\u00ednaj\u00edc\u00edch se mechanism\u016f, anal\u00fdza centr\u00e1ln\u00edch obvod\u016f chuti k j\u00eddlu v prodlou\u017een\u00e9 m\u00ed\u0161e vs. hypothalamu, testy simult\u00e1nn\u00ed obsazenosti receptor\u016f<\/li>\n<li><strong>Gastrick\u00e9 vyprazd\u0148ov\u00e1n\u00ed a postprandi\u00e1ln\u00ed fyziologie<\/strong> \u2014 doba vyprazd\u0148ov\u00e1n\u00ed \u017ealudku p\u0159i kombinovan\u00e9 l\u00e9\u010db\u011b vs. individu\u00e1ln\u00ed l\u00e9\u010db\u011b, postprandi\u00e1ln\u00ed dynamika gluk\u00f3zy, integrace st\u0159evn\u011b-hormon\u00e1ln\u00ed osy<\/li>\n<li><strong>V\u00fdzkum energetick\u00e9ho v\u00fddeje<\/strong> \u2014 klidov\u00fd energetick\u00fd v\u00fddej, respira\u010dn\u00ed kvocient; kombinace CagriSema vytv\u00e1\u0159\u00ed odli\u0161n\u00fd profil ve srovn\u00e1n\u00ed s multiagonisty obsahuj\u00edc\u00edmi glukagonov\u00fd receptor (mazdutide, retatrutide), proto\u017ee \u017e\u00e1dn\u00e1 ze slo\u017eek neaktivuje glukagonov\u00fd receptor<\/li>\n<li><strong>V\u00fdzkum designu kombinovan\u00e9 farmakologie<\/strong> \u2014 CagriSema jako p\u0159\u00edpadov\u00e1 studie fixn\u00edho pom\u011bru formulace v\u00edce peptid\u016f, srovn\u00e1n\u00ed farmakokinetiky spole\u010dn\u00e9ho slo\u017een\u00ed vs. sekven\u010dn\u00edho nebo sou\u010dasn\u00e9ho pod\u00e1v\u00e1n\u00ed samostatn\u00fdch vialek.<\/li>\n<\/ul>\n<p>Pro \u0161ir\u0161\u00ed kontext viz na\u0161e individu\u00e1ln\u00ed <a href=\"https:\/\/medsbase.com\/cs\/cagrilintide\/\">Cagrilintide<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a> str\u00e1nky produkt\u016f pro farmakologii na \u00farovni slo\u017eek, <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> jako hlavn\u00ed alternativu jednomolekul\u00e1rn\u00edho trojit\u00e9ho agonisty, a <a href=\"https:\/\/medsbase.com\/cs\/tirzepatide\/\">Tirzepatide<\/a> jako dvojit\u00e9ho GLP-1\/GIP kompar\u00e1toru. Proch\u00e1zejte celou <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\">katalog v\u00fdzkumn\u00fdch peptid\u016f<\/a> pro p\u0159\u00edbuzn\u00e9 slou\u010deniny.<\/p>\n<h2>Dostupn\u00e9 konfigurace<\/h2>\n<p>MedsBase skladuje sm\u011bs CagriSema v jedin\u00e9m spole\u010dn\u00e9m slo\u017een\u00ed: <strong>5 mg cagrilintidu + 5 mg semaglutidu na lahvi\u010dku<\/strong> v klinick\u00e9m hmotnostn\u00edm pom\u011bru 1:1. Vialka je dostupn\u00e1 v balen\u00ed po 10 nebo 20 vialk\u00e1ch s \u00fapln\u00fdmi pokyny pro rekonstituci:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Slo\u017een\u00ed vialky<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typick\u00fd v\u00fdzkumn\u00fd p\u0159\u00edpad u\u017eit\u00ed<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Velikosti balen\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>5 mg + 5 mg<\/strong> (cagri + sema)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standardn\u00ed v\u00fdzkumn\u00e1 sm\u011bs CagriSema \u2014 kombinace v\u00fdzkumu obezity, diabetu 2. typu a aditivn\u00ed farmakologie v klinick\u00e9m hmotnostn\u00edm pom\u011bru 1:1<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Ob\u011b slo\u017eky jsou dod\u00e1v\u00e1ny s HPLC \u010distotou \u226599% (ka\u017ed\u00e1 ov\u011b\u0159ena individu\u00e1ln\u011b) a p\u0159edem sm\u00edch\u00e1ny v jedn\u00e9 lyofilizovan\u00e9 lahvi\u010dce. Slo\u017een\u00ed 5 mg + 5 mg na lahvi\u010dku podporuje p\u0159ibli\u017en\u011b 2 t\u00fddny klinicky ekvivalentn\u00edho d\u00e1vkov\u00e1n\u00ed (2,4 mg + 2,4 mg t\u00fddn\u011b) na lahvi\u010dku \u2014 balen\u00ed 10 lahvi\u010dek pokryje p\u0159ibli\u017en\u011b 20 t\u00fddn\u016f v\u00fdzkumu p\u0159i udr\u017eovac\u00ed d\u00e1vce f\u00e1ze 3. Ve srovn\u00e1n\u00ed s n\u00e1kupem 10 lahvi\u010dek samostatn\u00e9ho Cagrilintidu (5 mg) plus 10 lahvi\u010dek samostatn\u00e9ho Semaglutidu (5 mg) zvl\u00e1\u0161\u0165 nab\u00edz\u00ed koformulovan\u00e1 sm\u011bs m\u00edrnou \u00fasporu n\u00e1klad\u016f a praktick\u00e9 pohodl\u00ed jednoduch\u00e9 rekonstituce z jedn\u00e9 lahvi\u010dky.<\/p>\n<h2>Srovn\u00e1n\u00ed \u2014 CagriSema vs Retatrutid<\/h2>\n<p>CagriSema a <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> jsou dva hlavn\u00ed v\u00edce\u00fa\u010delov\u00e9 p\u0159\u00edstupy k maxim\u00e1ln\u00edmu \u00fa\u010dinku na t\u011blesnou hmotnost v sou\u010dasn\u00e9m v\u00fdzkumu metabolick\u00fdch peptid\u016f. Pou\u017e\u00edvaj\u00ed z\u00e1sadn\u011b odli\u0161n\u00e9 konstruk\u010dn\u00ed p\u0159\u00edstupy: CagriSema kombinuje dva agonist\u00e9 jednotliv\u00fdch receptor\u016f ve fixn\u00ed d\u00e1vkov\u00e9 sm\u011bsi, zat\u00edmco retatrutid integruje trojitou farmakologii receptor\u016f do jedn\u00e9 molekuly. Oba dosahuj\u00ed srovnateln\u00fdch \u00fa\u010dink\u016f na t\u011blesnou hmotnost ve f\u00e1z\u00edch 2\/3 t\u011bmito odli\u0161n\u00fdmi cestami \u2014 toto srovn\u00e1n\u00ed je jedn\u00edm z nej\u010dast\u011bji citovan\u00fdch v sou\u010dasn\u00e9m v\u00fdzkumu farmakologie obezity.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Krit\u00e9rium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">CagriSema<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Retatrutide<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Konstruk\u010dn\u00ed p\u0159\u00edstup<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Kombinace dvou agonist\u016f jednotliv\u00fdch receptor\u016f<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Jedna molekula s trojit\u00fdm agonistick\u00fdm \u00fa\u010dinkem<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Profil receptoru<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + Amylin\/Kalcitonin<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">GLP-1 + GIP + Glukagon<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Slo\u017een\u00ed<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Cagrilintide + Semaglutide<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Jedna molekula (LY3437943)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>V\u00fdvoj\u00e1\u0159<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Novo Nordisk<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Eli Lilly<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Vliv na t\u011blesnou hmotnost<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~20\u201323 % (REDEFINE-1, 68 t\u00fddn\u016f)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~24 % (f\u00e1ze 2, 48 t\u00fddn\u016f)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Soulad polo\u010dasu rozpadu<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~159 \/ ~165 hodin (dob\u0159e slad\u011bno)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~6 dn\u00ed (jedna molekula, nen\u00ed t\u0159eba slad\u011bn\u00ed)<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>\u0160\u00ed\u0159e mechanismu \u00fa\u010dinku<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Centr\u00e1ln\u00ed sn\u00ed\u017een\u00ed chuti k j\u00eddlu + sytost v mozkov\u00e9m kmeni + potla\u010den\u00ed glukagonu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Centr\u00e1ln\u00ed sn\u00ed\u017een\u00ed chuti k j\u00eddlu + GIP-zprost\u0159edkovan\u00e1 lipol\u00fdza + glukagonem \u0159\u00edzen\u00fd energetick\u00fd v\u00fddej<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Energetick\u00fd v\u00fddej<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">M\u00edrn\u00fd (bez glukagonov\u00e9 slo\u017eky)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">V\u00fdznamn\u00fd (s glukagonovou slo\u017ekou)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Farmakologick\u00e1 volba mezi CagriSemou a retatrutidem z\u00e1vis\u00ed na v\u00fdzkumn\u00e9 ot\u00e1zce. Pro v\u00fdzkum zam\u011b\u0159en\u00fd na maxim\u00e1ln\u00ed \u00fa\u010dinek na t\u011blesnou hmotnost s nej\u010dist\u0161\u00edm profilem receptorov\u00e9 selektivity (bez ne\u017e\u00e1douc\u00ed signalizace GIP nebo glukagonu) je CagriSema preferovanou referenc\u00ed. Pro v\u00fdzkum zam\u011b\u0159en\u00fd na \u0161ir\u0161\u00ed mechanismy, kter\u00e9 poskytuje aktivace glukagonov\u00e9ho receptoru (v\u00fddej energie, mobilizace jatern\u00edch lipid\u016f), je retatrutid kanonick\u00fdm kompar\u00e1torem. Ot\u00e1zka kombinace versus jednomolekulov\u00e9ho designu je sama o sob\u011b aktivn\u00ed oblast\u00ed farmaceutick\u00e9ho v\u00fdzkumu \u2014 oba p\u0159\u00edstupy dos\u00e1hly pokro\u010dil\u00e9ho stadia v\u00fdvoje a studie f\u00e1ze 3 head-to-head pravd\u011bpodobn\u011b ur\u010d\u00ed dlouhodob\u00e9ho v\u00edt\u011bze.<\/p>\n<h2>Skladov\u00e1n\u00ed a rekonstituce<\/h2>\n<p><strong>P\u0159ed rekonstituci:<\/strong> Skladujte lyofilizovan\u00e9 lahvi\u010dky v chladni\u010dce p\u0159i 2\u20138 \u00b0C v p\u016fvodn\u00edm obalu pro kr\u00e1tkodob\u00e9 pracovn\u00ed z\u00e1soby. Pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch lahvi\u010dek zmrazte p\u0159i \u221220 \u00b0C. Lyofilizovan\u00e1 kombinace CagriSema je stabiln\u00ed v chladni\u010dce a\u017e 24 m\u011bs\u00edc\u016f a p\u0159i \u221220 \u00b0C a\u017e 36 m\u011bs\u00edc\u016f. Oba peptidov\u00e9 komponenty maj\u00ed velmi podobn\u00e9 profily stability, tak\u017ee skladov\u00e1n\u00ed je ur\u010deno t\u00edm, kter\u00fd peptid se za dan\u00fdch podm\u00ednek rozkl\u00e1d\u00e1 jako prvn\u00ed \u2014 v praxi jsou oba komponenty pozoruhodn\u011b podobn\u00e9. Vyhn\u011bte se cykl\u016fm zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed lyofilizovan\u00e9ho pr\u00e1\u0161ku.<\/p>\n<p><strong>Postup rekonstituce:<\/strong> Injektujte bakteriostatickou vodu po stran\u011b lahvi\u010dky (ne p\u0159\u00edmo na lyofilizovan\u00fd kol\u00e1\u010d). Proto\u017ee lahvi\u010dka obsahuje celkovou hmotnost peptid\u016f 10 mg (5 mg cagri + 5 mg sema), rekonstituce 2,0 ml vytvo\u0159\u00ed pracovn\u00ed koncentraci celkov\u00e9ho peptidu 5 mg\/ml \u2014 ekvivalentn\u00ed 2,5 mg\/ml ka\u017ed\u00e9 jednotliv\u00e9 slo\u017eky. P\u0159ibli\u017en\u011b 0,96 ml pod\u00e1v\u00e1 klinicky ekvivalentn\u00ed v\u00fdzkumnou d\u00e1vku 2,4 mg + 2,4 mg. Jemn\u011b zakru\u017ete \u2014 net\u0159epejte \u2014 a nechte 5\u201310 minut pro \u00fapln\u00e9 rozpu\u0161t\u011bn\u00ed (oba peptidy jsou acylovan\u00e9 a rozpou\u0161t\u011bj\u00ed se pomaleji ne\u017e men\u0161\u00ed neupraven\u00e9 peptidy). Spr\u00e1vn\u011b rekonstituovan\u00fd roztok by m\u011bl b\u00fdt \u010dir\u00fd a bezbarv\u00fd bez viditeln\u00fdch \u010d\u00e1stic. <strong>ne<\/strong> Skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C a pou\u017eijte do 30 dn\u016f pro optim\u00e1ln\u00ed stabilitu obou slo\u017eek. Nerozmrazujte rekonstituovan\u00fd roztok \u2014 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed degraduj\u00ed integritu peptid\u016f a mohly by nep\u0159im\u011b\u0159en\u011b ovlivnit kteroukoli slo\u017eku. Zlikvidujte jakoukoli lahvi\u010dku, kter\u00e1 vykazuje z\u00e1kal, sra\u017eeniny nebo zm\u011bnu barvy.<\/p>\n<p><strong>Po rekonstituci:<\/strong> Uchov\u00e1vejte v chladni\u010dce p\u0159i teplot\u011b 2\u20138 \u00b0C a spot\u0159ebujte do 30 dn\u016f pro optim\u00e1ln\u00ed stabilitu obou slo\u017eek. Rekonstituovan\u00fd roztok nezmrazujte \u2013 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed naru\u0161uj\u00ed integritu peptidu a mohly by nepom\u011brn\u011b ovlivnit jednu ze slo\u017eek. Ve\u0161ker\u00e9 lahvi\u010dky vykazuj\u00edc\u00ed z\u00e1kal, sra\u017eeninu nebo zm\u011bnu barvy zlikvidujte.<\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>K \u010demu se CagriSema pou\u017e\u00edv\u00e1 ve v\u00fdzkumu?<\/h3>\n<p>CagriSema se pou\u017e\u00edv\u00e1 v laboratorn\u00edm v\u00fdzkumu zkoumaj\u00edc\u00edm aditivn\u00ed farmakologii aktivace receptor\u016f GLP-1 a amylinu, kombina\u010dn\u00ed farmakologii obezity, preklinick\u00e9 modely diabetu 2. typu, srovn\u00e1vac\u00ed studie head-to-head proti jednomolekul\u00e1rn\u00edm multiagonist\u016fm (tirzepatid, retatrutid, mazdutid, survodutid) a ot\u00e1zky designu kombina\u010dn\u00ed farmakologie. Jedn\u00e1 se o hlavn\u00ed slou\u010deninu kombina\u010dn\u00ed farmakologie ve f\u00e1zi 3 v sou\u010dasn\u00e9m v\u00fdzkumu metabolick\u00fdch peptid\u016f spole\u010dnosti Novo Nordisk. Zde prod\u00e1van\u00fd v\u00fdzkumn\u00fd CagriSema je <strong>ne<\/strong> schv\u00e1len\u00fd FDA a je dod\u00e1v\u00e1n v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkumn\u00e9 \u00fa\u010dely.<\/p>\n<h3>Ka\u017ed\u00e1 lahvi\u010dka obsahuje<\/h3>\n<p>5 mg cagrilintidu a 5 mg semaglutidu <strong>5 mg cagrilintide a 5 mg semaglutide<\/strong>, spole\u010dn\u011b formulovan\u00e9 a lyofilizovan\u00e9 do jedin\u00e9ho pr\u00e1\u0161ku. Hmotnostn\u00ed pom\u011br 1:1 odpov\u00edd\u00e1 fixn\u00ed d\u00e1vce pou\u017eit\u00e9 v klinick\u00e9m programu CagriSema ve 3. f\u00e1zi (2.4 mg + 2.4 mg t\u00fddn\u011b). Oba peptidy se rekonstituuj\u00ed sou\u010dasn\u011b po p\u0159id\u00e1n\u00ed bakteriostatick\u00e9 vody.<\/p>\n<h3>Jak se CagriSema li\u0161\u00ed od samotn\u00e9ho Cagrilintidu nebo samotn\u00e9ho Semaglutidu?<\/h3>\n<p>CagriSema kombinuje oba peptidy v jedn\u00e9 lahvi\u010dce. <a href=\"https:\/\/medsbase.com\/cs\/cagrilintide\/\">aktivuje pouze rodinu receptor\u016f amylinu\/kalcitoninu a v monoterapeutick\u00e9m v\u00fdzkumu f\u00e1ze 2 zp\u016fsobuje p\u0159ibli\u017en\u011b 10% sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti.<\/a> aktivuje pouze rodinu receptor\u016f amylin\/calcitonin a vede k p\u0159ibli\u017en\u011b 10% sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti ve v\u00fdzkumu monoterapie f\u00e1ze 2. <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Pouh\u00fd semaglutid<\/a> aktivuje pouze receptor GLP-1 a v monoterapii f\u00e1ze 3 (studie STEP) vede k p\u0159ibli\u017en\u011b 15% redukci t\u011blesn\u00e9 hmotnosti. Kombinace CagriSema dosahuje p\u0159ibli\u017en\u011b 20\u201323% \u2013 co\u017e je v\u00edce ne\u017e u ka\u017ed\u00e9 slo\u017eky samostatn\u011b, proto\u017ee tyto dva mechanismy se nep\u0159ekr\u00fdvaj\u00ed (r\u016fzn\u00e9 receptory, r\u016fzn\u00e9 oblasti CNS, komplement\u00e1rn\u00ed perifern\u00ed \u00fa\u010dinky).<\/p>\n<h3>Jak se CagriSema li\u0161\u00ed od retatrutidu?<\/h3>\n<p>Oba p\u0159edstavuj\u00ed vedouc\u00ed v\u00edce mechanism\u016f p\u0159\u00edstupy k ovlivn\u011bn\u00ed t\u011blesn\u00e9 hmotnosti, ale vyu\u017e\u00edvaj\u00ed z\u00e1sadn\u011b odli\u0161n\u00e9 konstruk\u010dn\u00ed cesty. CagriSema kombinuje dva samostatn\u00e9 agonisty jednotliv\u00fdch receptor\u016f (cagrilintid + semaglutid) v jedn\u00e9 lahvi\u010dce \u2013 jde o kombinovanou farmakologii. <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> vyu\u017e\u00edv\u00e1 trojreceptorovou farmakologii (GLP-1 + GIP + glukagon) v jedn\u00e9 molekule. Oba dosahuj\u00ed p\u0159ibli\u017en\u011b 20\u201324% \u00fa\u010dinku na t\u011blesnou hmotnost p\u0159i udr\u017eovac\u00ed d\u00e1vce ve v\u00fdzkumu f\u00e1ze 2\/3, ale prost\u0159ednictv\u00edm r\u016fzn\u00fdch soubor\u016f receptor\u016f \u2013 CagriSema vyu\u017e\u00edv\u00e1 GLP-1 + amylin, retatrutid vyu\u017e\u00edv\u00e1 GLP-1 + GIP + glukagon.<\/p>\n<h3>Pro\u010d kombinovat dva peptidy v jedn\u00e9 lahvi\u010dce?<\/h3>\n<p>Spole\u010dn\u00e1 formulace m\u00e1 t\u0159i praktick\u00e9 v\u00fdhody: (1) polo\u010dasy cagrilintidu (~159 h) a semaglutidu (~165 h) jsou dob\u0159e slad\u011bn\u00e9, tak\u017ee jedin\u00e1 t\u00fddenn\u00ed injekce dod\u00e1v\u00e1 oba peptidy podle stejn\u00e9ho farmakokinetick\u00e9ho sch\u00e9matu; (2) rekonstituce je jednodu\u0161\u0161\u00ed \u2013 jedna lahvi\u010dka, jeden objem \u0159edidla, jedno odb\u011brn\u00e9 mno\u017estv\u00ed; (3) v\u00fdzkum s pevn\u00fdm pom\u011brem d\u00e1vek je p\u0159\u00edmo\u010dar\u00fd, proto\u017ee pom\u011br d\u00e1vek je nastaven p\u0159i v\u00fdrob\u011b a nem\u016f\u017ee se m\u011bnit mezi jednotliv\u00fdmi odb\u011bry z lahvi\u010dek. Hlavn\u00ed kompromis je v tom, \u017ee pom\u011br d\u00e1vek je pevn\u011b nastaven na hmotnostn\u00ed pom\u011br 1:1 \u2013 pro v\u00fdzkum vy\u017eaduj\u00edc\u00ed r\u016fzn\u00e9 pom\u011bry mohou b\u00fdt up\u0159ednost\u0148ov\u00e1ny samostatn\u00e9 lahvi\u010dky <a href=\"https:\/\/medsbase.com\/cs\/cagrilintide\/\">cagrilintide<\/a> a <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">semaglutide<\/a> Jak\u00e1 je typick\u00e1 v\u00fdzkumn\u00e1 d\u00e1vka CagriSema?.<\/p>\n<h3>Jak\u00e1 je typick\u00e1 v\u00fdzkumn\u00e1 d\u00e1vka CagriSema?<\/h3>\n<p>Publikovan\u00fd klinick\u00fd v\u00fdzkum 3. f\u00e1ze pou\u017e\u00edv\u00e1 jako udr\u017eovac\u00ed d\u00e1vku 2,4 mg cagrilintidu + 2,4 mg semaglutidu t\u00fddn\u011b, s n\u011bkolikam\u011bs\u00ed\u010dn\u00edm titra\u010dn\u00edm sch\u00e9matem za\u010d\u00ednaj\u00edc\u00edm na 0,25 mg + 0,25 mg. Lahvi\u010dka rekonstituovan\u00e1 2,0 ml bakteriostatick\u00e9 vody poskytuje 2,5 mg\/ml ka\u017ed\u00e9 slo\u017eky (5 mg\/ml celkov\u00e9 peptidov\u00e9 hmotnosti) \u2014 p\u0159ibli\u017en\u011b 0,96 ml odpov\u00edd\u00e1 klinicky ekvivalentn\u00ed v\u00fdzkumn\u00e9 d\u00e1vce 2,4 mg + 2,4 mg.<\/p>\n<h3>Je CagriSema schv\u00e1lena FDA?<\/h3>\n<p>Ne. CagriSema nen\u00ed schv\u00e1lena FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. F\u00e1ze 3 studi\u00ed REDEFINE-1 (obezita) a REDEFINE-2 (T2DM) v letech 2024\u20132025 p\u0159inesla pozitivn\u00ed v\u00fdsledky, ale regula\u010dn\u00ed pod\u00e1n\u00ed a p\u0159ezkum st\u00e1le prob\u00edhaj\u00ed. Ve\u0161ker\u00e1 CagriSema prod\u00e1van\u00e1 dodavateli pouze pro v\u00fdzkumn\u00e9 \u00fa\u010dely je ur\u010dena pro laboratorn\u00ed v\u00fdzkum a nem\u011bla by b\u00fdt pod\u00e1v\u00e1na lidem.<\/p>\n<h3>Jak by m\u011bla b\u00fdt CagriSema skladov\u00e1na?<\/h3>\n<p>Lyofilizovan\u00e9 lahvi\u010dky: kr\u00e1tkodob\u011b skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C, dlouhodob\u011b neotev\u0159en\u00e9 lahvi\u010dky p\u0159i \u221220 \u00b0C. Rekonstituovan\u00fd roztok: skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C, pou\u017eijte do 30 dn\u016f. Rekonstituovan\u00fd roztok nezmrazujte \u2014 cykly zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed degraduj\u00ed integritu peptidu a mohly by nep\u0159im\u011b\u0159en\u011b ovlivnit kteroukoli slo\u017eku. V\u017edy chra\u0148te p\u0159ed p\u0159\u00edm\u00fdm sv\u011btlem.<\/p>\n<h3>Jak rekonstituovat CagriSema?<\/h3>\n<p>Postupujte podle v\u00fd\u0161e uveden\u00e9ho rekonstitu\u010dn\u00edho postupu. P\u0159idejte bakteriostatickou vodu po stran\u011b lahvi\u010dky (ne p\u0159\u00edmo na lyofilizovanou hmotu), jemn\u011b zakru\u017ete a nechte 5\u201310 minut pro \u00fapln\u00e9 rozpu\u0161t\u011bn\u00ed (oba peptidy jsou acylovan\u00e9 a rozpou\u0161t\u011bj\u00ed se pomaleji ne\u017e men\u0161\u00ed neupraven\u00e9 peptidy). Ne <strong>ne<\/strong> prot\u0159ep\u00e1vejte lahvi\u010dku. Oba peptidy se rekonstituuj\u00ed sou\u010dasn\u011b ze stejn\u00e9 lahvi\u010dky. Spr\u00e1vn\u011b rekonstituovan\u00fd roztok je \u010dir\u00fd a bezbarv\u00fd, bez viditeln\u00fdch \u010d\u00e1stic. Pro lahvi\u010dku + 2,0 ml \u0159edidla je pracovn\u00ed koncentrace 2,5 mg\/ml ka\u017ed\u00e9ho peptidu.<\/p>\n<h3>Jak\u00e9 konfigurace MedsBase nab\u00edz\u00ed?<\/h3>\n<p>MedsBase nab\u00edz\u00ed CagriSema jako koformulaci v jedin\u00e9m slo\u017een\u00ed: 5 mg cagrilintidu + 5 mg semaglutidu na lahvi\u010dku (hmotnostn\u00ed pom\u011br 1:1, lyofilizovan\u00e9). Lahvi\u010dka je dostupn\u00e1 v balen\u00ed po 10 nebo 20 kusech. Ka\u017ed\u00e1 slo\u017eka je individu\u00e1ln\u011b ov\u011b\u0159ena na \u010distotu \u226599 % HPLC s certifik\u00e1tem anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed.<\/p>\n<h3>Mohu koupit slo\u017eky CagriSema samostatn\u011b?<\/h3>\n<p>Ano \u2014 MedsBase nab\u00edz\u00ed oba peptidov\u00e9 komponenty jako samostatn\u00e9 produkty: <a href=\"https:\/\/medsbase.com\/cs\/cagrilintide\/\">Cagrilintide<\/a> v lahvi\u010dk\u00e1ch po 5 mg a 10 mg, a <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a> v lahvi\u010dk\u00e1ch po 2\u201350 mg. Samostatn\u00e9 lahvi\u010dky jsou u\u017eite\u010dn\u00e9, pokud v\u00fdzkumn\u00e9 protokoly vy\u017eaduj\u00ed jin\u00e9 d\u00e1vkov\u00e9 pom\u011bry ne\u017e klinick\u00fd hmotnostn\u00ed pom\u011br 1:1, nebo pokud v\u00fdzkumn\u00edci cht\u011bj\u00ed d\u00e1vkovat cagrilintid a semaglutid nez\u00e1visle. Koformulovan\u00e1 sm\u011bs nab\u00edz\u00ed malou \u00fasporu a pohodl\u00ed rekonstituce z jedn\u00e9 lahvi\u010dky pro protokoly s klinick\u00fdm pom\u011brem 1:1.<\/p>\n<h3>Zp\u016fsobuje CagriSema vedlej\u0161\u00ed \u00fa\u010dinky ve v\u00fdzkumu?<\/h3>\n<p>Profil vedlej\u0161\u00edch \u00fa\u010dink\u016f CagriSema ve v\u00fdzkumu f\u00e1ze 3 je dominov\u00e1n gastrointestin\u00e1ln\u00edmi p\u0159\u00edznaky spole\u010dn\u00fdmi pro ob\u011b slo\u017eky: nevolnost, p\u0159echodn\u00e9 potla\u010den\u00ed chuti k j\u00eddlu a opo\u017ed\u011bn\u00e9 vyprazd\u0148ov\u00e1n\u00ed \u017ealudku jsou z\u00e1visl\u00e9 na d\u00e1vce a maj\u00ed tendenci se zm\u00edr\u0148ovat b\u011bhem 4\u20138 t\u00fddn\u016f kontinu\u00e1ln\u00edho pod\u00e1v\u00e1n\u00ed. Kombinovan\u00fd re\u017eim nezp\u016fsobuje kvalitativn\u011b odli\u0161n\u00e9 vedlej\u0161\u00ed \u00fa\u010dinky ne\u017e kter\u00e1koli slo\u017eka samostatn\u011b \u2014 tolerance gastrointestin\u00e1ln\u00edho traktu je zhruba srovnateln\u00e1 s monoterapi\u00ed semaglutidem v ekvivalentn\u00edch d\u00e1vk\u00e1ch.<\/p>\n<h3>Jak\u00fd je polo\u010das rozpadu CagriSemy?<\/h3>\n<p>Ob\u011b peptidov\u00e9 slo\u017eky maj\u00ed velmi podobn\u00fd plazmatick\u00fd polo\u010das rozpadu: cagrilintid ~159 hodin (~6,5 dne) a semaglutid ~165 hodin (~7 dn\u00ed). Tato shoda je jedn\u00edm z konstruk\u010dn\u00edch prvk\u016f, kter\u00e9 umo\u017e\u0148uj\u00ed praktick\u00e9 spole\u010dn\u00e9 formulov\u00e1n\u00ed v jedn\u00e9 lahvi\u010dce \u2014 oba peptidy jsou z ob\u011bhu odstra\u0148ov\u00e1ny ve stejn\u00e9m \u010dasov\u00e9m r\u00e1mci, co\u017e podporuje t\u00fddenn\u00ed d\u00e1vkov\u00e1n\u00ed bez rozd\u00edln\u00e9 farmakokinetiky. Mechanismus vazby na albumin (C20\/C18 acylace mastn\u00fdch kyselin) je z\u00e1kladem prodlou\u017een\u00e9ho polo\u010dasu rozpadu u obou peptid\u016f.<\/p>\n<h3>Jak dlouho trv\u00e1, ne\u017e se \u00fa\u010dinky CagriSemy projev\u00ed v preklinick\u00e9m v\u00fdzkumu?<\/h3>\n<p>Akutn\u00ed farmakodynamick\u00e9 \u00fa\u010dinky na vyprazd\u0148ov\u00e1n\u00ed \u017ealudku, sytost po j\u00eddle a gluk\u00f3zovou toleranci jsou detekovateln\u00e9 ji\u017e n\u011bkolik hodin po prvn\u00ed d\u00e1vce. \u00da\u010dinky na t\u011blesnou hmotnost u ob\u00e9zn\u00edch hlodavc\u016f se obvykle st\u00e1vaj\u00ed statisticky v\u00fdznamn\u00fdmi po 1\u20132 t\u00fddnech t\u00fddenn\u00edho d\u00e1vkov\u00e1n\u00ed a d\u00e1le se zvy\u0161uj\u00ed po dobu 16\u201324 t\u00fddn\u016f. Maxim\u00e1ln\u00ed \u00fa\u010dinek na t\u011blesn\u00e9 slo\u017een\u00ed se rozv\u00edj\u00ed b\u011bhem 48\u201368 t\u00fddn\u016f, co\u017e odpov\u00edd\u00e1 trajektorii f\u00e1ze 3 studie REDEFINE-1.<\/p>\n<h3>Mohu si objednat CagriSemu pro mezin\u00e1rodn\u00ed p\u0159epravu?<\/h3>\n<p>Ano. MedsBase expeduje CagriSemu po cel\u00e9m sv\u011bt\u011b prost\u0159ednictv\u00edm na\u0161\u00ed specializovan\u00e9 s\u00edt\u011b pro p\u0159epravu peptid\u016f. Objedn\u00e1vky obsahuj\u00edc\u00ed pouze peptidy jsou zp\u016fsobil\u00e9 pro na\u0161i samostatnou slu\u017ebu p\u0159epravy peptid\u016f. V\u0161echny objedn\u00e1vky jsou odes\u00edl\u00e1ny v termoregulovan\u00e9m balen\u00ed s kompletn\u00edm sledov\u00e1n\u00edm a jsou pokryty na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed peptidy pro v\u00fdzkum metabolismu, t\u011blesn\u00e9ho slo\u017een\u00ed a multi-mechanism\u016f<\/h2>\n<ul>\n<li><a href=\"\/cs\/cagrilintide\/\"><strong>Cagrilintide<\/strong><\/a> \u2014 Dlouhodob\u011b p\u016fsob\u00edc\u00ed analog amylinu \u2014 amylinov\u00e1 slo\u017eka CagriSemy, samostatn\u00e9 lahvi\u010dky<\/li>\n<li><a href=\"\/cs\/semaglutide\/\"><strong>Semaglutide<\/strong><\/a> \u2014 Dlouhodob\u011b p\u016fsob\u00edc\u00ed agonista GLP-1 \u2014 GLP-1 slo\u017eka CagriSemy, samostatn\u00e9 lahvi\u010dky<\/li>\n<li><a href=\"\/cs\/retatrutide\/\"><strong>Retatrutide<\/strong><\/a> \u2014 Trojit\u00fd agonista GLP-1\/GIP\/glukagon \u2014 alternativn\u00ed multi-agonistick\u00e1 molekula<\/li>\n<li><a href=\"\/cs\/tirzepatide\/\"><strong>Tirzepatide<\/strong><\/a> \u2014 Dvojit\u00fd agonista GLP-1\/GIP \u2014 alternativn\u00ed multi-mechanick\u00fd p\u0159\u00edstup<\/li>\n<li><a href=\"\/cs\/mazdutide\/\"><strong>Mazdutide<\/strong><\/a> \u2014 Dvojit\u00fd ko-agonista GLP-1\/glukagon \u2014 alternativn\u00ed odvozen\u00fd od oxyntomodulinu<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Dal\u0161\u00ed \u010dten\u00ed<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Prozkoumejte kombinovanou farmakologii metabolick\u00e9ho pole<\/strong><\/p>\n<p style=\"margin: 0;\">Prohl\u00e9dn\u011bte si celou <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\"><strong>katalog v\u00fdzkumn\u00fdch peptid\u016f<\/strong><\/a>, s p\u0159\u00edbuzn\u00fdmi kombinovan\u00fdmi a multi-mechanick\u00fdmi slou\u010deninami v\u010detn\u011b <a href=\"https:\/\/medsbase.com\/cs\/cagrilintide\/\">Cagrilintide<\/a> (samostatn\u00fd amylin), <a href=\"https:\/\/medsbase.com\/cs\/semaglutide\/\">Semaglutide<\/a> (samostatn\u00fd GLP-1), <a href=\"https:\/\/medsbase.com\/cs\/retatrutide\/\">Retatrutide<\/a> (jednomolekul\u00e1rn\u00ed trojit\u00fd agonista), a <a href=\"https:\/\/medsbase.com\/cs\/mazdutide\/\">Mazdutide<\/a> (du\u00e1ln\u00ed GLP-1\/glukagon). Srovn\u00e1vac\u00ed pr\u016fvodce: <a href=\"https:\/\/medsbase.com\/cs\/retatrutide-vs-tirzepatide\/\">Retatrutide vs Tirzepatide<\/a>.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 Kombinace cagrilintidu a semaglutidu v pom\u011bru 1:1<br \/>\n\u2705 Ob\u011b peptidy v jedn\u00e9 lahvi\u010dce (5 mg + 5 mg)<br \/>\n\u2705 Vedouc\u00ed kombinace spole\u010dnosti Novo Nordisk ve f\u00e1zi 3 pro obezitu<br \/>\n\u2705 Efekt sn\u00ed\u017een\u00ed t\u011blesn\u00e9 hmotnosti ~20\u201323 % (studie REDEFINE-1)<br \/>\n\u2705 Komplement\u00e1rn\u00ed mechanismy amylinu a GLP-1<\/p>\n<p><strong>CagriSema<\/strong> je kombinovan\u00fd peptidov\u00fd p\u0159\u00edpravek.<\/p>","protected":false},"featured_media":70943,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6284,6287,5441,3846],"class_list":{"0":"post-70765","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-cagrilintide","8":"product_tag-cagrisema","9":"product_tag-peptide","10":"product_tag-semaglutide","12":"first","13":"instock","14":"shipping-taxable","15":"purchasable","16":"product-type-variable","17":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/70765","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=70765"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/70943"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=70765"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=70765"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=70765"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=70765"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}